Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Results: We found that EA patients with at least one minor allele of the SNP rs9622682 had significantly lower levels of serum IL-6 (p=0.003 GA genotype and p=0.002 AA genotype). In addition, we observed that EA patients with AA genotype for rs9622682 showed higher levels of serum Gal1 and an increased expression of Gal1 on peripheral blood lymphocytes measured by WB compared to GG patients. That SNP showed partial linkage disequilibrium (LD) (R2=0.6) with the rs929039 located in the LGALS1 promoter. The presence of minor alleles of rs929039 displayed a similar effect over IL-6 and Gal1 levels than rs9622682. Different combinations of minor alleles of those SNPs could amplify the increased expression of Gal1 observed in EA patients. On the other hand, treatment of anti-CD3/CD28-stimulated lymphocytes with recombinant Gal1 reduced IL-6 in vitro expression levels in healthy donors.
Conclusion: The presence of minor alleles of SNPs of LGALS1 rs9622682 and rs929039 may affect the expression of Gal1 and this finding is associated with lower levels of IL-6 in serum of patients with EA, suggesting a potential prognostic value for these genetic variants.
To cite this abstract in AMA style:Lamana A, Triguero-Martinez A, V. Seoane I, de la Fuente H, Martinez-Mora C, Ortiz Garcia AM, García-Vicuña R, Gomariz RP, Gonzalez-Alvaro I. Galectin 1 As Potential Prognostic Biomarker in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/galectin-1-as-potential-prognostic-biomarker-in-rheumatoid-arthritis/. Accessed November 18, 2019.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/galectin-1-as-potential-prognostic-biomarker-in-rheumatoid-arthritis/